To evaluate the efficacy of Mipragoside, a ganglioside derivative, in vernal keratoconjunctivitis we performed a controlled randomised clinical trial involving 24 patients (mean age 10+/-3.4 years, range 5-20 years). Patients received either Mipragoside 0.5% aqueous ophthalmic gel or placebo four times a day for 2 weeks after a week of treatment with placebo, Ocular signs and symptoms were evaluated and considered for statistical analysis, Results show that Mipragoside significantly reduces all symptoms, being most effective on itching (p = 0.01; p = 0.0001) and hyperaemia (p = 0.01; p = 0.0006) after 1 and 2 weeks respectively when compared with placebo, Physician judgement of drug efficacy at the end of treatment was significantly in favour of Mipragoside (p = 0.0001) compared with placebo, We conclude that Mipragoside topical treatment improves symptoms of patients,vith vernal keratoconjunctivitis and we postulate a possible anti-inflammatory activity of this compound.

Centofanti, M., Schiavone, M., Lambiase, A., Taffara, M., Giuffrida, S., Bonini, S. (1996). Efficacy of mipragoside ophthalmic gel in vernal keratoconjunctivitis. EYE, 10(4), 422-424.

Efficacy of mipragoside ophthalmic gel in vernal keratoconjunctivitis

CENTOFANTI, MARCO;
1996-04-01

Abstract

To evaluate the efficacy of Mipragoside, a ganglioside derivative, in vernal keratoconjunctivitis we performed a controlled randomised clinical trial involving 24 patients (mean age 10+/-3.4 years, range 5-20 years). Patients received either Mipragoside 0.5% aqueous ophthalmic gel or placebo four times a day for 2 weeks after a week of treatment with placebo, Ocular signs and symptoms were evaluated and considered for statistical analysis, Results show that Mipragoside significantly reduces all symptoms, being most effective on itching (p = 0.01; p = 0.0001) and hyperaemia (p = 0.01; p = 0.0006) after 1 and 2 weeks respectively when compared with placebo, Physician judgement of drug efficacy at the end of treatment was significantly in favour of Mipragoside (p = 0.0001) compared with placebo, We conclude that Mipragoside topical treatment improves symptoms of patients,vith vernal keratoconjunctivitis and we postulate a possible anti-inflammatory activity of this compound.
apr-1996
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/30 - MALATTIE APPARATO VISIVO
English
Con Impact Factor ISI
ganglioside; mipragoside; unclassified drug; adolescent; adult; antiinflammatory activity; article; child; clinical article; clinical trial; controlled clinical trial; controlled study; drug efficacy; female; human; hyperemia; male; pruritus; randomized controlled trial; statistical analysis; symptom; topical drug administration; vernal conjunctivitis; Administration, Topical; Adolescent; Adult; Child; Child, Preschool; Conjunctivitis, Allergic; Female; G(M1) Ganglioside; Gels; Humans; Male; Treatment Outcome
Centofanti, M., Schiavone, M., Lambiase, A., Taffara, M., Giuffrida, S., Bonini, S. (1996). Efficacy of mipragoside ophthalmic gel in vernal keratoconjunctivitis. EYE, 10(4), 422-424.
Centofanti, M; Schiavone, M; Lambiase, A; Taffara, M; Giuffrida, S; Bonini, S
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/53064
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact